Comprehensive pan-cancer analysis of MEX3A in human tumors Authors: Xuezhong Zhang, Yongxin Pan, Ning Li, Meilin Gao, Tingting Chu, Xuebin Zhang Published: 2026 ABSTRACT AbstractMEX3A is an evolutionarily conserved RNA-binding protein characterized by two KH RNA-binding domains and a C-terminal RING domain, suggesting potential roles in both post-transcriptional regulation and protein modification. Although MEX3A has been implicated in several individual cancer types, its shared and cancer-specific roles across human cancers remain incompletely understood. In this study, we performed a comprehensive pan-cancer analysis of MEX3A by integrating publicly available datasets, including TCGA, GTEx, CPTAC, and other external resources. We systematically evaluated MEX3A expression, genetic alterations, phosphorylation status, clinical relevance, RNA modification-related associations, immune-related features, and functional enrichment profiles across multiple tumor types. MEX3A was significantly upregulated in most cancers and showed associations with advanced pathological stage in several tumor types. Survival analyses indicated that elevated MEX3A expression was correlated with poor overall survival and disease-specific survival in cancers such as ACC, LIHC, MESO, and SARC, supporting its potential value as a prognostic biomarker. Genetic alteration analysis revealed frequent copy number amplification of MEX3A in several cancers, whereas these alterations were not consistently associated with survival outcomes. Proteomic analyses further identified altered phosphorylation levels at S338 and S462 in tumor tissues, suggesting that post-translational modification may contribute to the regulation of MEX3A activity in a cancer-type-specific manner. Correlation analyses showed that MEX3A expression was associated with RNA modification-related genes, immune modulators, immune checkpoint genes, tumor-infiltrating immune cells, tumor mutational burden, and microsatellite instability across different cancers. These findings suggest that MEX3A may participate in RNA regulatory networks and tumor-immune microenvironment interactions. Functional enrichment analysis revealed that MEX3A-associated proteins are involved in pathways related to transcriptional dysregulation, mRNA stability, and translational regulation. However, as these findings are primarily based on bioinformatic and correlation-based analyses, they should not be interpreted as evidence that MEX3A is a validated therapeutic or immunotherapy target. Overall, this study provides a systematic pan-cancer characterization of MEX3A and supports its potential role as a prognostic biomarker and a hypothesis-generating candidate for future mechanistic and clinical validation.Supplementary InformationThe online version contains supplementary material available at 10.1007/s12672-026-05459-2.Keywords: MEX3A, Pan-cancer analysis, Prognostic biomarker, Immune regulation, Tumor microenvironment Introduction In recent years, the rapid advancements in bioinformatics have provided transformative insights into cancer research, enabling the identification of key molecular players across various cancer types [1, 2]. Pan-cancer research focuses on the exploration of shared and distinct molecular mechanisms across various cancers. This approach leverages large-scale, multi-dimensional datasets from initiatives like The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) project [3–7]. These datasets enable bioinformatics methodologies to assess gene expression, genetic alterations, and their correlations with clinical parameters. The human MEX3 (muscle excess 3) family is an evolutionarily conserved RNA-binding protein (RBP) family consisting of four members, MEX3A-D, which display distinct expression patterns and biological functions [8–10]. MEX3A is an important member of this family and is encoded on chromosome 1q22. MEX3A, a key member of the MEX3 family, is encoded on chromosome 1q22 [9]. Structurally, MEX3A contains two K homology (KH) domains that mediate RNA binding and a C-terminal RING domain with potential E3 ubiquitin ligase activity [8]. This unique structural organization suggests that MEX3A may exert dual regulatory functions by modulating both RNA metabolism and protein modification [11]. Compared with many conventional RNA-binding proteins, this combined “RNA regulation plus protein modification” property indicates that MEX3A may participate in tumorigenesis through complex post-transcriptional and post-translational mechanisms. Previous studies have reported that MEX3A contributes to tumor progression in several malignancies, including including breast cancer (BRCA) [12], colon cancer (COAD) [13], glioma [10], liver cancer (LIHC) [14, 15], lung adenocarcinoma (LUAD) [16], ovarian cancer (OV) [17], and thyroid cancer (THCA) [18]. These studies suggest that MEX3A may regulate cancer cell proliferation, apoptosis, epithelial-mesenchymal transition, ferroptosis, therapeutic resistance, and immune-related processes. However, most available studies have focused on individual cancer types, and a comprehensive pan-cancer analysis of MEX3A remains limited. Therefore, it is necessary to systematically evaluate whether MEX3A has shared or cancer-specific roles across different tumor contexts. Although other MEX3 family members may also be involved in cancer biology, MEX3A was prioritized in the present study based on its distinctive dual-domain structure, accumulating cancer-related evidence, and preliminary bioinformatic observations showing broad dysregulation, prognostic relevance, and cancer-type-specific phosphorylation changes. Thus, this study aimed to perform a comprehensive pan-cancer analysis of MEX3A by integrating gene expression, protein expression, genetic alterations, phosphorylation, prognosis, RNA modification-related genes, immune infiltration, immune modulators, TMB/MSI, and functional enrichment analyses. This MEX3A-centered analysis may help clarify its potential contribution to tumor progression and provide a basis for future mechanistic and translational studies. Materials and methods Gene expression analysis RNA-seq data for ENSG00000254726 (MEX3A) in TPM format was obtained from UCSC XENA (https://xenabrowser.net/datapages/) for the TCGA and GTEx datasets, processed via the Toil pipeline [19]. Expression levels of the MEX3A gene were analyzed across various samples, focusing on both cancerous and normal tissues. The analysis was performed using R software (version 4.2.1) and the ggplot2 package (version 3.4.4). Data retrieval from the TCGA_GTEx dataset at UCSC [13] enabled a threshold of |log2 fold change (LogFC)| ≥ 1, with statistical significance set at P < 0.01. Unpaired Wilcoxon Rank Sum and Signed Rank Tests were conducted, and boxplots were generated for visualization using ggplot2. Violin plots were produced with the GEPIA2 tool (http://gepia2.cancer-pku.cn) to display MEX3A expression across different cancer stages [20]. The UALCAN portal (http://ualcan.path.uab.edu/analysis-prot.html), an interactive web resource for analyzing cancer omics data, was used to perform protein expression analysis of the CPTAC (Clinical Proteomic Tumor Analysis Consortium) dataset [21]. Specifically, we investigated the expression levels of total protein and phosphoprotein (phosphorylated at the S338 and S462 sites) of MEX3A in primary tumor and normal tissues by querying “MEX3A.” Survival prognosis analysis The TCGA Pan-Cancer dataset was retrieved from UCSC (https://xenabrowser.net/) [19]. Expression data for ENSG00000254726 (MEX3A) were extracted, alongside survival data from a published TCGA prognostic study. Samples with follow-up times shorter than 30 days were excluded. Cox proportional hazards regression analysis was conducted using the survival package (version 3.3.1) in R. Heatmaps and forest plots were created using ggplot2 (version 3.4.4) to visualize the results. Statistical significance was assessed with a Log-rank test (P < 0.05). Genetic alteration analysis Data on genetic alterations, including mutation frequency, mutation types, site-specific mutations, and copy number variations (CNA), were collected via cBioPortal (http://www.cbioportal.org/) [22]. The TCGA project provided a comprehensive dataset covering multiple cancer types. Additionally, overall survival (OS) and disease-specific survival (DSS) were compared between tumors with and without MEX3A alterations using cBioPortal’s “Comparison” function. RNA modification, immune checkpoints, and immune moderator genes of MEX3A A standardized pan-cancer dataset was downloaded from UCSC (https://xenabrowser.net/) [19]. Expression data for ENSG00000254726 (MEX3A) and 44 marker genes associated with three RNA modification types (m1A, m5C, m6A) were extracted [23]. Expression data for 150 immune moderator genes from five pathways (chemokine, receptor, MHC, immunoinhibitor, and immunostimulator) and 60 immune checkpoint genes (inhibitory and stimulatory) were also obtained [24]. The expression values were log2-transformed, and associations were analyzed using the corrplot (version 0.90) and psych (version 2.1.6) packages in R software (version 4.2.1). Heatmaps were generated with ggplot2 (version 3.4.4) packages to illustrate relationships. Immune infiltration analysis MEX3A expression and immune infiltration correlations were evaluated using TIMER2 [25]. Heatmaps and scatter plots visualized associations with various immune cell types. Immune infiltration was quantified using algorithms such as TIMER, EPIC, xCell, MCPCOUNTER, CIBERSORT-ABS, QUANTISEQ, and CIBERSORT. Tumor mutational burden (TMB) and microsatellite instability (MSI) Expression data for ENSG00000254726 (MEX3A) were extracted from the TCGA Pan-Cancer dataset via UCSC (https://xenabrowser.net/). TMB data were obtained from the GDC portal and processed using MuTect2 [26]. TMB scores were calculated with the maftools package (version 2.8.05). MSI scores were retrieved from a previous study [27]. Correlations between MEX3A expression and both TMB and MSI were analyzed in R software (version 4.2.1). MEX3A-related gene enrichment analysis The STRING database (https://cn.string-db.org/) identified proteins interacting with MEX3A, using a minimum interaction score of 0.40 and a maximum of 50 interactors [28]. GEPIA2 identified the top 100 genes correlated with MEX3A in TCGA datasets [20]. Pearson correlation analysis was performed to evaluate the relationship between MEX3A and the selected genes, and a dot plot of the mean log2TPM values was generated. Heatmaps were created using the “Gene_Corr” module in TIMER2 [25]. Partial correlation coefficients and P-values were calculated using the purity-adjusted Spearman’s rank correlation method. Additionally, tumor purity-adjusted Spearman’s rank correlation was analyzed using appropriate statistical tests. Kyoto Encyclopedia of Genes and Genomes (KEGG) [29] and Gene Ontology (GO) [30] enrichment analyses were conducted using the “clusterProfiler” package (version 4.4.4) in R software (version 4.2.1). Circular charts illustrating the results were generated with the ggplot2 package (version 3.4.4). Statistical significance was defined as P < 0.05 and false discovery rate (FDR) < 0.25. Results Gene expression analysis data We analyzed MEX3A expression using the TCGA and GTEx datasets available through the UCSC database, comparing cancerous tissues with their normal counterparts. Comprehensive statistical analyses were conducted, and the expression levels of MEX3A across different cancer types are detailed in Supplementary Table 1. As illustrated in Fig. 1A, MEX3A expression was significantly elevated in several cancers, including ACC, BLCA, BRCA, CHOL, COAD, DLBC, ESCA, GBM, HNSC, KIRC, KIRP, LGG, LIHC, LUAD, LUSC, OV, PAAD, PRAD, READ, SKCM, STAD, TGCT, THCA, THYM, UCEC, and UCS. Conversely, its expression was markedly reduced in KICH and LAML. Protein expression levels, assessed using the CPTAC dataset, revealed reduced levels in BRCA, while GBM, LUSC, and UCEC exhibited elevated protein expression compared to normal tissues (Fig. 1B). Additional analysis with the GEPIA2 online tool indicated a significant correlation between MEX3A expression and tumor stage in several cancers, including ACC (P = 0.00741), BRCA (P = 0.0217), KICH (P = 0.00633), LIHC (P = 0.0483), OV (P = 0.0000943), PAAD (P = 0.0282), and TGCT (P = 0.00425) (Fig. 1C). These findings provide valuable insights into MEX3A’s role in various cancer types and its potential involvement in tumor progression. MEX3A Expression in Various Tumor Types and Pathological Stages. A The levels of MEX3A were evaluated across multiple tumor types (*P < 0.05, **P < 0.01, ***P < 0.001). B MEX3A protein expression levels, analyzed using the CPTAC dataset (*P < 0.05, **P < 0.01, ***P < 0.001). C MEX3A expression was analyzed at different tumor stages (stages I-IV) in several cancers, including ACC (P = 0.00741), BRCA (P = 0.0217), KICH (P = 0.00633), LIHC (P = 0.0483), OV (P = 0.0000943), PAAD (P = 0.0282), and TGCT (P = 0.00425) Survival prognosis analysis We examined the prognostic significance of MEX3A expression across multiple cancers by stratifying tumors into high and low expression groups based on TCGA data. The relationship between MEX3A expression and overall survival (OS) for each cancer type is detailed in Supplementary Table 2. As depicted in Fig. 2A, higher MEX3A expression was significantly associated with poorer OS in ACC (P = 4.63e-05), LIHC (P = 0.0233), MESO (P = 0.0001), and SARC (P = 0.0005). Conversely, lower MEX3A expression was linked to worse OS outcomes in THYM (P = 0.0489) and UCS (P = 0.0081). The relationship between MEX3A expression and disease-specific survival (DSS) is presented in Supplementary Table 3. Elevated MEX3A levels were associated with poorer DSS in ACC (P = 6.85e-05), BRCA (P = 0.0063), LIHC (P = 0.0083), MESO (P = 0.0020), SARC (P = 0.0046), and UVM (P = 0.0350). In contrast, lower MEX3A expression negatively impacted DSS in UCS (P = 0.0186) (Fig. 2B). These findings suggest that MEX3A is a critical prognostic biomarker in various cancers, influencing both OS and DSS outcomes. Relationship Between MEX3A Expression and Tumor Prognosis in TCGA. The association between MEX3A gene expression and survival outcomes in various tumors within the TCGA dataset was explored. Both overall survival (A) and disease-specific survival (B) were included in the study. (*P < 0.05, **P < 0.01, ***P < 0.001) Genetic alteration analysis The frequency and types of MEX3A gene alterations across different cancers were assessed using TCGA data. As shown in Fig. 3A, the highest frequency of MEX3A alterations was observed in UCS (17.54%), predominantly “amplification,” followed by LIHC (11.29%) and CHOL (11.11%), which were also characterized by “amplification.” Additional cancers, including UCEC, BRCA, LUAD, BLCA, and OV, displayed alteration frequencies of 8.88%, 8.21%, 7.77%, 6.57%, and 6.34%, respectively, with “amplification” as the primary genetic variation in these cases. In some cancers, including UCS, CHOL, PCPG, SARC, THYM, MESO, and KIRC, “amplification” was the sole genetic alteration detected. Figure 3B highlights other genetic mutations in MEX3A, with missense mutations being the most common. For instance, an A398T missense mutation was identified in a COAD case. However, no significant differences were observed in OS (P = 0.925) or DSS (P = 0.561) between patients with and without MEX3A alterations in COAD (Fig. 3C and D). These results highlight the genetic variability of MEX3A and its potential clinical implications in cancer. MEX3A Mutation Characteristics in TCGA Across Multiple Cancers. MEX3A mutation patterns in various cancers from the TCGA database were analyzed using the cBioPortal platform. A Mutation Type Frequency: The frequency of different mutation types was illustrated to highlight mutation diversity. B Mutation Site Frequency: The frequency of mutations at specific sites was displayed to provide detailed insights into affected location. C Survival Correlation: The potential association between MEX3A mutation status and overall and disease-specific survival in COAD was examined using cBioPortal Protein phosphorylation analysis data We compared the phosphorylation levels of MEX3A between normal and primary tumor tissues using the CPTAC dataset, focusing on four tumor types: BRCA (Normal, n = 18; Tumor, n = 125), LUAD(Normal, n = 102; Tumor, n = 111), LUSC(Normal, n = 102; Tumor, n = 110), and OV(Normal, n = 19; Tumor, n = 84). At the S338 locus, MEX3A phosphorylation was significantly lower in BRCA tissues compared to normal tissues (Fig. 4A, P < 0.05). In contrast, phosphorylation at the S338 locus was significantly higher in LUAD, LUSC, and OV tissues relative to normal tissues (Fig. 4B and D, all P < 0.05). Additionally, the S462 locus of MEX3A exhibited a markedly higher phosphorylation level in OV tissues compared to normal tissues (Fig. 4E, P < 0.01). These findings warrant further molecular investigations to elucidate the potential role of S462 phosphorylation in tumorigenesis. Protein phosphorylation analysis data. The phosphorylation levels of MEX3A between normal and primary tumor tissues using the CPTAC dataset were compared, focusing on four tumor types: BRCA, LUAD, LUSC, and OV. At the S338 locus, MEX3A phosphorylation was significantly lower in BRCA tissues compared to normal tissues (Fig. 4A, P < 0.05). In contrast, phosphorylation at the S338 locus was significantly higher in LUAD, LUSC, and OV tissues relative to normal tissues. (Figure 4B and D, all P < 0.05). Additionally, the S462 locus of MEX3A exhibited a markedly higher phosphorylation level in OV tissues compared to normal tissues (Fig. 4E, P < 0.01) RNA modification Emerging research has demonstrated the critical role of RNA modifications in cancer progression, including angiogenesis [31, 32]. Detailed correlation coefficients and P-values for RNA modification analysis of MEX3A across various tumor types are provided in Supplementary Table 4. Figure 5 reveals a strong positive correlation between MEX3A and several RNA modification-related genes, particularly those involved in m1A, m5C, and m6A modifications. These correlations were statistically significant in multiple cancers, including DLBC, THYM, UCEC, TGCT, PRAD, THCA, PAAD, KIRC, PCPG, CHOL, SARC, LGG, GBM, MESO, BLCA, LUAD, LUSC, UVM, KICH, READ, STAD, KIRP, OV, CESC, HNSC, ESCA, SKCM, ACC, and LIHC. Furthermore, MEX3A demonstrated a positive association with specific m5C-modifying enzymes, such as DNMT3A, and m6A-modifying enzymes, including RBM15B, across all cancers examined. These findings suggest that RNA modifications may be associated with MEX3A expression, indicating a potential mechanistic link between MEX3A and RNA modification pathways. RNA Modification Analysis of MEX3A Across Different Tumors. A strong positive correlation exists between MEX3A and several RNA modification-related genes, particularly those involved in m1A, m5C, and m6A modifications. (*P < 0.05, **P < 0.01, ***P < 0.001) Immune infiltration analysis Tumor-infiltrating immune cells, critical components of the tumor microenvironment (TME), play pivotal roles in tumor progression and development [33]. Using several computational algorithms, including TIMER, CIBERSORT, CIBERSORT-ABS, TIDE, xCell, MCPCOUNTER, QUANTISEQ, and EPIC, we analyzed the correlation between immune cell infiltration and MEX3A expression across various tumors in the TCGA dataset. As shown in Fig. 6A and B, MEX3A expression positively correlated with cancer-associated fibroblasts (CAFs) in CESC, ESCA, HNSC, HNSC-HPV-, HNSC-HPV+, KIRC, LUSC, OV, and PAAD. We also further explore the relationships between MEX3A and ESTIMATE score across various tumors. MEX3A expression positively correlated with THCA. MEX3A expression negatively associated with BLCA, GBM, KIRP, SARC, STAD, and UCEC (Supplementary Fig. 1). These findings underscore the intricate interactions between MEX3A and the TME in different cancer types. Correlation Between MEX3A Expression and Cancer-Associated Fibroblast (CAF) Infiltration. MEX3A expression was positively correlated with cancer-associated fibroblasts (CAFs) in CESC, ESCA, HNSC, HNSC-HPV-, HNSC-HPV+, KIRC, LUSC, OV, and PAAD. (*P < 0.05, **P < 0.01, ***P < 0.001) MEX3A and immune checkpoints & immune modulator genes To explore the relationship between MEX3A and immune regulation, we performed a comprehensive correlation analysis between MEX3A expression and immune checkpoint and modulator genes. Detailed results are presented in Supplementary Table 5. Figure 7 shows that MEX3A consistently exhibited a positive correlation with immune inhibitory genes, including VEGFA and CD276, across multiple cancers. Similarly, a positive correlation was observed with the immune stimulatory gene HMGB1 in various tumor types. In contrast, MEX3A showed a negative correlation with immune stimulatory genes such as TNFRSF14, GZMA, and CCL5 in several cancers. Correlation Between MEX3A Expression and Immune Checkpoints. MEX3A consistently exhibited a positive correlation with immune inhibitory genes, including VEGFA and CD276, across multiple cancers. (*P < 0.05, **P < 0.01, ***P < 0.001) The relationship between MEX3A expression and immune modulator genes is detailed in Supplementary Table 6. Figure 8 highlights positive correlations of MEX3A with various chemokine receptors, MHC genes, immunoinhibitors, and immunostimulators in UCS and MESO. Conversely, negative correlations were observed in cancers such as DLBC, THYM, THCA, GBM, LGG, BLCA, SARC, TGCT, LAML, SKCM, and KIRP. Specifically, MEX3A demonstrated negative associations with chemokines, including CCL5, XCL2, CXCL10, CXCL11, CXCL13, CCL3, and CCL4, and MHC molecules such as B2M, HLA-E, HLA-F, HLA-A, HLA-B, HLA-C, and others across various cancers. Immunoinhibitors, including TGFBR1, VTCN1, and KDR, exhibited positive correlations with MEX3A in a wide range of tumor types, while immunostimulators such as BTNL2, TNFRSF25, PVR, ULBP1, CD276, and TNFRSF13C also showed positive associations. In contrast, negative correlations were noted for immunostimulators like KLRC1, TNFRSF17, TNFRSF14, TNFRSF13, and C10orf54 across multiple cancers. These findings reveal complex and cancer-specific relationships between MEX3A and immune-related genes. Correlation Between MEX3A Expression and Immune Modulator Genes. Positive correlations of MEX3A with various chemokine receptors, MHC genes, immunoinhibitors, and immunostimulators in UCS and MESO. Conversely, negative correlations were observed in cancers such as DLBC, THYM, THCA, GBM, LGG, BLCA, SARC, TGCT, LAML, SKCM, and KIRP. Specifically, MEX3A demonstrated negative associations with chemokines, including CCL5, XCL2, CXCL10, CXCL11, CXCL13, CCL3, and CCL4, and MHC molecules such as B2M, HLA-E, HLA-F, HLA-A, HLA-B, HLA-C, and others across various cancers. Immunoinhibitors, including TGFBR1, VTCN1, and KDR, exhibited positive correlations with MEX3A in a wide range of tumor types, while immunostimulators such as BTNL2, TNFRSF25, PVR, ULBP1, CD276, and TNFRSF13C also showed positive associations. (*P < 0.05, **P < 0.01, ***P < 0.001) In the E-MTAB-11,058 (UM) dataset, MEX3A expression levels were significantly reduced in anti-PD-1-treated MP41, UM22, and 92 − 1 cells compared to the control group, suggesting that MEX3A may be associated with immunotherapy response (Supplementary Fig. 2). MEX3A and tumor mutational burden (TMB) and microsatellite instability (MSI) We examined the association of MEX3A expression with tumor mutational burden (TMB) and microsatellite instability (MSI) across various cancers. The original data on these correlations are presented in Supplementary Tables 7 and 8, respectively. Figure 9A demonstrates a positive correlation between MEX3A expression and TMB in cancers such as ACC, BLCA, BRCA, KICH, LAML, LGG, LUAD, LUSC, PRAD, and THYM. Conversely, a negative correlation was observed in cancers such as COAD, SKCM, UCEC, and UCS. Figure 9B illustrates a positive correlation between MEX3A expression and MSI in cancers including BLCA, CESC, LUAD, and LUSC, whereas a negative correlation was found in COAD and DLBC. These findings suggest that MEX3A may contribute to genomic instability, influencing cancer development through its association with TMB and MSI. We further explored the relationship between MEX3A expression and mismatch repair genes, including MLH1, MSH2, MSH6, PMS2, and EPCAM across multiple tumor types. MEX3A expression was positively correlated with these genes in most of tumors. (Supplementary Fig. 3). MEX3A’s Correlation with Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI). A Tumor Mutational Burden (TMB): MEX3A expression exhibited a positive correlation with TMB in cancers such as ACC, BLCA, BRCA, KICH, LAML, LGG, LUAD, LUSC, PRAD, and THYM. Conversely, a negative correlation was observed in cancers such as COAD, SKCM, UCEC, and UCS. (B) Microsatellite Instability (MSI): a positive correlation between MEX3A expression and MSI in cancers including BLCA, CESC, LUAD, and LUSC, whereas a negative correlation was found in COAD and DLBC. (*P < 0.05, **P < 0.01, ***P < 0.001) Enrichment analysis of MEX3A-related genes To elucidate the mechanistic role of MEX3A in cancer development, we identified MEX3A-binding proteins and correlated genes. Using the STRING database, we identified 36 proteins interacting with MEX3A (Fig. 10A). Concurrently, the GEPIA2 platform was used to retrieve the top 100 genes most strongly correlated with MEX3A expression. As shown in Fig. 10B, significant positive correlations were observed between MEX3A and HDAC2 (R = 0.57), ILF2 (R = 0.58), SOX4 (R = 0.63), VPS72 (R = 0.61), and ZBTB12 (R = 0.64), all with P-values < 0.001. The heatmap in Fig. 10C further underscores these associations across different cancers. An intersection analysis of the two groups identified UBAP2L as the only common gene (Fig. 10D). Gene Ontology (GO) and KEGG pathway enrichment analyses were conducted to further explore the functional roles of MEX3A in cancer biology. GO analysis revealed enrichment in terms such as “regulation of translation,” “regulation of mRNA stability,” “ribonucleoprotein granule,” and “single-stranded RNA binding,” indicating their relevance to MEX3A-driven tumor processes. KEGG analysis identified critical pathways, including herpes simplex virus 1 infection, microRNAs in cancer, transcriptional misregulation in cancer, and thermogenesis, which may mediate the oncogenic effects of MEX3A (Fig. 10E and F). These findings provide valuable insights into the multifaceted role of MEX3A in tumorigenesis and its influence on key cellular processes. MEX3A-Related Gene Enrichment Analysis. A The STRING tool was used to obtain experimentally verified MEX3A-binding proteins. B The top 100 MEX3A-correlated genes in TCGA projects were identified through GEPIA2, and expression correlations between MEX3A and genes such as HDAC2 (R = 0.57), ILF2 (R = 0.58), SOX4 (R = 0.63), VPS72 (R = 0.61), and ZBTB12 (R = 0.64), all with P-values < 0.001. C A heatmap was generated to show the corresponding data for various cancer types. D The intersection analysis of the two groups identified UBAP2L as the only common gene. E GO enrichment analysis was performed on MEX3A-binding and interacting genes. F KEGG pathway analysis was conducted based on MEX3A-binding and interacting genes Discussion This study underscores the importance of MEX3A in cancer biology, highlighting its dual roles as a potential oncogene and context-dependent biomarker. The differential expression of MEX3A observed in various cancers underscores its multifaceted role in tumor biology. Elevated MEX3A levels in cancers such as ACC, BLCA, and LUAD (Fig. 1A) suggest its involvement in oncogenic processes, potentially through its regulation of mRNA stability and post-transcriptional modifications. In contrast, reduced MEX3A expression in KICH and LAML highlights its possible context-dependent function, which aligns with previous studies indicating that certain RNA-binding proteins exhibit tumor-suppressive or oncogenic roles depending on the tissue context. At the protein level, discrepancies between transcriptomic and proteomic findings, as seen in BRCA and LUSC (Fig. 1B), suggest that post-transcriptional regulation or protein turnover mechanisms may influence MEX3A’s function. The significant association between MEX3A expression and tumor stage in cancers such as ACC, BRCA, and LIHC (Fig. 1C) supports its potential role in promoting tumor progression. Higher MEX3A levels in advanced-stage tumors may indicate its involvement in processes such as cell proliferation, invasion, or metastasis. For instance, elevated expression in OV and PAAD correlates with more aggressive disease phenotypes, emphasizing its relevance as a marker of tumor advancement. The findings highlight MEX3A’s potential as a prognostic biomarker. Increased expression correlates with worse outcomes in several cancers, such as ACC and LIHC, suggesting that MEX3A drives aggressive tumor behavior. These observations are consistent with studies implicating RNA-binding proteins in enhancing oncogenic signaling pathways [34, 35]. Conversely, reduced MEX3A expression in cancers like KICH and LAML raises the possibility of therapeutic strategies aimed at restoring its function in these contexts. MEX3A’s diverse roles across cancer types suggest that targeting it could provide novel therapeutic opportunities, particularly in cancers characterized by elevated expression. Our analysis reveals a strong association between MEX3A expression levels and survival outcomes across multiple cancers. Elevated MEX3A expression is significantly linked to poorer OS in cancers such as ACC, LIHC, MESO, and SARC, highlighting its potential role as a driver of aggressive tumor behavior. Similarly, DSS outcomes further corroborate MEX3A’s association with adverse prognosis in ACC, BRCA, LIHC, and MESO. These findings suggest that MEX3A functions as an oncogenic factor in these cancer types, consistent with previous studies implicating RNA-binding proteins in promoting tumor progression through the regulation of oncogenic transcripts and pathways [35, 36]. Conversely, lower MEX3A expression correlates with worse OS and DSS outcomes in cancers such as THYM and UCS. This dichotomy underscores the context-dependent nature of MEX3A’s function, which may vary based on the tumor microenvironment, genetic background, and associated signaling pathways. For example, in certain cancer types, MEX3A may play a tumor-suppressive role by stabilizing transcripts critical for normal cellular function [35, 37]. The correlation between MEX3A expression and survival outcomes may be explained by its regulatory functions at the RNA level. Elevated MEX3A expression likely enhances the stability and translation of oncogenic mRNAs, thereby promoting proliferation, metastasis, and resistance to apoptosis. For instance, MEX3A’s interaction with key regulators of mRNA stability, such as SOX4 and HDAC2 [38], suggests its involvement in transcriptional misregulation and epigenetic modifications, both of which are hallmarks of cancer. On the other hand, reduced MEX3A expression in certain cancers may impair the maintenance of tumor-suppressive signaling pathways, potentially contributing to more aggressive disease phenotypes. Our analysis of TCGA data reveals that MEX3A undergoes genetic alterations across a range of cancer types, with amplification being the predominant variation. The highest frequencies of MEX3A amplification were observed in UCS, LIHC, and CHOL, followed by UCEC, BRCA, LUAD, BLCA, and OV. The consistent association of MEX3A amplification with these cancers suggests that increased gene dosage may drive overexpression, thereby contributing to tumorigenesis. Notably, in cancers such as UCS, CHOL, and SARC, amplification appears to be the sole genetic alteration, underscoring its potential as a critical oncogenic mechanism in these tumors. Despite the prevalence of MEX3A alterations, no significant differences in OS or DSS were observed between patients with and without these alterations in COAD. This indicates that while MEX3A alterations may play a role in tumor initiation or progression, their direct impact on patient prognosis may be context-dependent and influenced by other molecular or clinical factors. The high frequency of MEX3A amplification in cancers such as UCS, LIHC, and CHOL, however, aligns with its elevated expression levels and poorer survival outcomes in these cancers, as observed in our survival analyses. This suggests that MEX3A amplification could serve as a molecular marker for aggressive tumor phenotypes, guiding the identification of high-risk patients. The oncogenic role of MEX3A amplification may be explained by its involvement in stabilizing and regulating transcripts critical for cell proliferation, differentiation, and survival. For instance, studies have shown that MEX3A can promote tumorigenesis by modulating the expression of genes involved in EMT and immune evasion [38]. Amplification-driven overexpression of MEX3A may amplify these oncogenic processes, leading to enhanced tumor growth and metastatic potential. Abnormal protein phosphorylation plays the role of a “regulatory switch” in the occurrence and development of tumors, which widely affects cell growth, survival, metabolism and microenvironment regulation [39]. Then, we also analyzed the phosphorylation levels of MEX3A in tumor and normal tissues across multiple cancer types, including BRCA, LUAD, LUSC, and OV, using data from the CPTAC dataset. Our findings provide insights into the differential regulation of MEX3A phosphorylation in various tumors and its potential implications for tumor biology and therapy. We observed that phosphorylation at the S338 locus of MEX3A was significantly reduced in BRCA tissues compared to normal tissues, while the same locus exhibited elevated phosphorylation in LUAD, LUSC, and OV tissues. This differential phosphorylation pattern suggests a tissue-specific modulation of MEX3A in various cancers. The variation in phosphorylation status may reflect a potential mechanistic distinction in how MEX3A functions in different tumor microenvironments. The increased phosphorylation of MEX3A at the S338 locus in LUAD, LUSC, and OV tissues might indicate its active involvement in tumor progression, suggesting that MEX3A phosphorylation at this site could play a role in regulating processes like cell proliferation, survival, and migration, which are hallmark features of cancer. Elevated phosphorylation levels of MEX3A at this locus could enhance its stability or alter its interaction with downstream signaling molecules, contributing to a pro-tumorigenic state. Interestingly, the S462 locus exhibited a significant increase in phosphorylation specifically in OV tissues. This finding warrants further investigation into the functional relevance of this phosphorylation event. Given that OV often exhibits distinct molecular characteristics compared to other tumor types, understanding the role of S462 phosphorylation in OV could provide new insights into the molecular pathways driving ovarian tumorigenesis and progression. The differential phosphorylation of MEX3A across tumor types suggests that it could be a promising target for therapeutic intervention. Targeting specific phosphorylation sites, such as S338 or S462, may offer a strategy to modulate the activity of MEX3A and its downstream signaling pathways. RNA modifications, including m1A, m5C, and m6A, are increasingly recognized as important components of cancer-associated RNA regulation [32]. By affecting RNA stability, splicing, translation, and localization, these modifications may contribute to tumor-related biological processes, including proliferation, metastasis, angiogenesis, and immune interactions [40]. In the present study, MEX3A expression was significantly correlated with multiple RNA modification-related genes across cancer types. In particular, positive correlations were observed between MEX3A and genes such as the m5C-related regulator DNMT3A and the m6A-related regulator RBM15B in several tumors, including DLBC, THYM, UCEC, and TGCT. These findings suggest that MEX3A may be associated with RNA modification-related regulatory programs in cancer. However, because the present analysis is based on transcriptomic correlations, it does not establish a direct interaction between MEX3A and RNA modification machinery or demonstrate that MEX3A regulates RNA modification activity. The observed associations may also reflect shared transcriptional states, tumor-cell composition, or other biological features of the analyzed tumors. Further experimental studies are therefore needed to determine whether and how MEX3A participates in RNA modification-related processes. The tumor microenvironment (TME) comprises malignant cells, stromal cells, immune cells, and extracellular matrix components that collectively influence tumor progression and therapeutic response [41]. Cancer-associated fibroblasts (CAFs), as an important stromal cell population, can contribute to extracellular matrix remodeling, angiogenesis, and immunosuppressive signaling [42, 43]. Our analysis identified positive correlations between MEX3A expression and estimated CAF infiltration in multiple cancers, including CESC, ESCA, HNSC, KIRC, LUSC, OV, and PAAD. These results indicate that increased MEX3A expression may be associated with a CAF-enriched microenvironment in selected tumor types. Such associations are potentially relevant because CAF-rich tumors have been linked to immune suppression and treatment resistance. Nevertheless, the current results do not demonstrate that MEX3A promotes CAF recruitment or function, nor do they establish direct interactions between MEX3A-expressing tumor cells and fibroblasts. Additional studies using single-cell or spatial transcriptomic approaches, together with functional experiments, will be required to clarify whether MEX3A is involved in stromal remodeling or merely reflects tumor microenvironmental characteristics. Our pan-cancer analysis further revealed significant associations between MEX3A expression and a range of immune-related genes, including immune checkpoint-related molecules, immune modulators, chemokines, and major histocompatibility complex genes [44]. MEX3A expression was positively correlated with several genes associated with immunosuppressive or tumor-promoting features, such as VEGFA and CD276, in multiple cancer types. In contrast, negative correlations were observed with immune activation- or immune recruitment-related genes, including TNFRSF14, GZMA, CCL5, CXCL10, CXCL13, HLA-A, and HLA-B, in specific tumors [45]. These findings suggest that MEX3A may be linked to distinct immune microenvironmental states in a cancer-type-dependent manner. Importantly, these correlations should not be interpreted as evidence that MEX3A directly controls immune checkpoint signaling, chemokine production, antigen presentation, or immune evasion. Instead, they identify MEX3A as a candidate immune-related molecule worthy of further investigation. Functional studies and analyses of clinically annotated immunotherapy cohorts are needed to determine whether MEX3A contributes mechanistically to immune regulation or can serve as a reproducible marker of immune-related tumor features. Tumor mutational burden (TMB) and microsatellite instability (MSI) have been widely investigated as biomarkers associated with response to immune checkpoint blockade [46, 47]. In our study, the association between MEX3A expression and TMB varied across cancer types. Positive correlations were detected in ACC, BLCA, BRCA, KICH, LAML, LGG, LUAD, LUSC, PRAD, and THYM, whereas negative correlations were observed in COAD, SKCM, UCEC, and UCS. Similarly, MEX3A expression was positively correlated with MSI in BLCA, CESC, LUAD, and LUSC, but negatively correlated with MSI in COAD and DLBC. These heterogeneous patterns indicate that the relationship between MEX3A expression and genomic instability-related features may be tumor-context dependent. However, the present findings do not demonstrate that MEX3A influences mutation accumulation, mismatch repair activity, or MSI development. Rather, the observed associations suggest that MEX3A expression may be evaluated as a potential marker associated with immunotherapy response-related characteristics, particularly when considered together with established biomarkers such as TMB, MSI, immune infiltration, and checkpoint expression. Although our correlation analyses suggested that MEX3A is associated with immune infiltration, immune checkpoint genes, TMB, MSI, and immune modulators, we acknowledge that expression-based correlation alone is insufficient to establish MEX3A as a candidate prognosis-associated and immune-associated molecule. Therefore, we further analyzed the publicly available E-MTAB-11,058 (UM) dataset to explore the relationship between MEX3A expression and immunotherapy response. In this dataset, MEX3A expression levels were significantly reduced in anti-PD-1-treated MP41, UM22, and 92 − 1 cells compared to the control group, suggesting that MEX3A may be associated with immunotherapy response. Nevertheless, these findings remain preliminary. Future studies using MEX3A knockdown or overexpression models are needed to determine whether MEX3A directly affects CD8 + T cell-mediated tumor cell killing and whether targeting MEX3A can enhance the therapeutic efficacy of anti-PD-1/PD-L1 therapy in vivo. The results support the hypothesis that MEX3A is associated with immune and microenvironmental features in several tumor types and may represent a promising candidate for further investigation in cancer immunology. Nevertheless, this study is primarily a systematic bioinformatics screening study designed to generate hypotheses and identify promising candidates for subsequent validation. The findings are based mainly on computational analyses of bulk transcriptomic datasets and inferred immune infiltration, which cannot establish causality or therapeutic efficacy. Therefore, MEX3A should not currently be regarded as a confirmed candidate prognosis-associated and immune-associated molecule. Future validation in independent patient cohorts, immunotherapy-treated populations, single-cell or spatial datasets, and mechanistic experimental models will be necessary to determine its biological function and clinical utility. Through protein-protein interaction (PPI) analysis using the STRING database, we identified 36 proteins interacting with MEX3A, highlighting its involvement in diverse cellular processes. Among the most correlated genes identified through GEPIA2 analysis, HDAC2, ILF2, SOX4, VPS72, and ZBTB12 stood out, with significant positive correlations. These interactions suggest that MEX3A may exert its oncogenic effects through the modulation of gene expression, RNA stability, and protein synthesis. For example: HDAC2, a histone deacetylase, is implicated in epigenetic regulation, tumor cell proliferation, and immune evasion, suggesting that MEX3A might influence chromatin remodeling [48]. SOX4, as the transcription factor, is involved in EMT and metastasis, aligning with MEX3A’s role in promoting aggressive tumor phenotypes [49]. ILF2, known for its role in RNA processing and stability, its correlation with MEX3A further supports the latter’s involvement in post-transcriptional regulation [50]. GO analysis revealed that MEX3A and its associated genes are enriched in key biological processes. Consistent with MEX3A’s known role as an RNA-binding protein, regulation of mRNA stability enrichment indicates its potential impact on oncogenic mRNA transcripts. MEX3A may be involved in stress granule dynamics, a mechanism often co-opted by cancer cells for survival under adverse conditions via ribonucleoprotein granule formation. Single-stranded RNA binding aligns with MEX3A’s potential to regulate specific RNA targets, further implicating it in post-transcriptional control mechanisms critical for tumorigenesis. KEGG analysis identified several pathways influenced by MEX3A, providing insights into its role in cancer biology. For instances, MEX3A’s regulation of miRNA-associated pathways suggests a role in modulating non-coding RNAs that influence tumor progression, metastasis, and therapeutic resistance. The pathway of transcriptional misregulation in cancer underscores MEX3A’s potential impact on gene expression profiles that drive tumorigenesis. While traditionally associated with viral biology, this pathway enrichment of herpes simplex virus 1 Infection may reflect the intersection of viral mimicry mechanisms and oncogenic processes mediated by MEX3A. The pathway of thermogenesis may be linked to metabolic reprogramming, a hallmark of cancer, suggesting that MEX3A might influence tumor metabolism. Our enrichment analysis highlights MEX3A as a central player in cancer biology, influencing pathways critical for tumor growth, survival, and progression. The strong correlations with genes and proteins involved in transcriptional regulation, RNA stability, and metabolic reprogramming position MEX3A as both a biomarker and candidate prognosis-associated and immune-associated molecule. Targeting MEX3A and its associated pathways offers a promising avenue for developing innovative cancer therapies tailored to tumor-specific molecular profiles. Overexpression of MEX3A may be driven, at least in part, by copy number amplification in several cancer types, including UCS, LIHC, and CHOL, suggesting that genomic alterations may serve as potential upstream mechanisms contributing to MEX3A dysregulation. In addition, differential phosphorylation of MEX3A at residues S338 and S462 indicates that post-translational modifications may regulate its functional activity, protein stability, or interactions with RNA molecules and protein partners. As an RNA-binding protein, MEX3A may also be involved in RNA modification-associated regulatory processes, as supported by its strong correlations with RNA modification regulators such as DNMT3A and RBM15B. These associations suggest that MEX3A may influence mRNA stability and translational efficiency through RNA modification-related mechanisms. Moreover, MEX3A-associated genes, including SOX4 and HDAC2, have been implicated in immune-related processes such as immune escape and antigen presentation, thereby providing a potential mechanistic link among MEX3A expression, immune infiltration, immune checkpoint regulation, and patient prognosis. Therefore, we propose that MEX3A may promote tumor progression through a regulatory cascade involving copy number amplification, transcriptional upregulation, phosphorylation-mediated functional modulation, RNA modification-related regulation, and altered expression of immune-related genes. However, the present study is primarily based on bioinformatic analyses, and these findings require further experimental validation. For example, CRISPR-mediated knockout and overexpression experiments should be performed in both in vitro and in vivo models to establish a causal relationship between MEX3A copy number amplification and transcriptional upregulation. Site-directed mutagenesis combined with phosphorylation-specific antibodies is needed to validate the regulatory roles of S338 and S462 phosphorylation in MEX3A functional activity and protein stability. RNA immunoprecipitation (RIP) and RNA modification detection approaches, such as MeRIP-seq, should be employed to directly confirm the involvement of MEX3A in RNA modifications, such as m⁶A, and its subsequent regulation of downstream target genes. Furthermore, co-immunoprecipitation (Co-IP) and luciferase reporter assays are required to elucidate the molecular regulatory network linking MEX3A with immune-related genes, including SOX4 and HDAC2. Accordingly, systematic gain- and loss-of-function experiments, together with validation in clinical samples, are necessary to more comprehensively and accurately define the precise role of MEX3A in tumor progression. Limitations This study has several limitations. First, most analyses were based on publicly available bulk transcriptomic, proteomic, and clinical datasets, including TCGA, GTEx, CPTAC, and other external resources. Although these datasets provide large-scale pan-cancer information, potential biases related to cohort composition, sample heterogeneity, platform differences, data preprocessing, and batch effects cannot be fully excluded. In addition, many immune-related analyses were based on computationally inferred immune infiltration and expression-based correlations, which may not accurately reflect the spatial distribution, functional status, or direct interactions of immune cells within the tumor microenvironment. Second, the present study was primarily designed as a systematic bioinformatics screening analysis to generate hypotheses regarding the potential role of MEX3A in cancer. Therefore, the observed associations between MEX3A expression and clinical outcomes, immune infiltration, immune checkpoint genes, tumor mutational burden, microsatellite instability, immune modulators, RNA modification-related genes, and signaling pathways should not be interpreted as evidence of causality. Although these findings suggest that MEX3A may be involved in tumor progression and tumor-immune interactions, they do not establish MEX3A as a confirmed candidate prognosis-associated and immune-associated molecule. Third, although copy number amplification, phosphorylation alterations, and RNA modification-related associations of MEX3A were identified, their functional consequences remain to be experimentally validated. For example, CRISPR-mediated knockout, overexpression, and rescue experiments are needed in both in vitro and in vivo models to clarify whether MEX3A copy number amplification directly drives transcriptional upregulation and tumor-promoting phenotypes. Similarly, site-directed mutagenesis, phosphorylation-specific antibodies, and protein stability assays are required to determine the biological relevance of MEX3A phosphorylation sites, particularly S338 and S462. RNA immunoprecipitation and RNA modification detection approaches, such as RIP-seq and MeRIP-seq, will also be necessary to verify whether MEX3A directly participates in RNA modification processes, including m⁶A-related regulation, and to identify its downstream targets. Fourth, although MEX3A showed significant associations with immune-related features, including immune checkpoint genes and immunotherapy-related indicators, these results remain preliminary. Analysis of the publicly available E-MTAB-11,058 uveal melanoma dataset showed that MEX3A expression was reduced in anti-PD-1-treated MP41, UM22, and 92 − 1 cells compared with controls, suggesting a possible relationship between MEX3A expression and immunotherapy response. However, this observation alone is insufficient to demonstrate that MEX3A directly regulates sensitivity to immune checkpoint blockade. Future studies using MEX3A knockdown or overexpression models are required to determine whether MEX3A affects CD8⁺ T cell-mediated tumor cell killing and whether targeting MEX3A can enhance the efficacy of anti-PD-1/PD-L1 therapy in vivo. Finally, the molecular mechanisms linking MEX3A to immune regulation and tumor progression remain incompletely understood. Further mechanistic studies, including co-immunoprecipitation, luciferase reporter assays, chromatin- or RNA-binding assays, single-cell sequencing, spatial transcriptomics, and validation in independent clinical cohorts, are needed to clarify the regulatory network involving MEX3A and immune-related genes such as SOX4 and HDAC2. Collectively, while our findings support MEX3A as a promising candidate for further investigation in cancer biology and tumor immunology, additional functional experiments, patient-derived models, immunotherapy-treated cohorts, and clinical validation are required before its biological function and therapeutic potential can be firmly established. Conclusion This comprehensive pan-cancer analysis suggests that MEX3A is closely associated with multiple aspects of cancer biology, including tumor progression, patient prognosis, RNA modification-related regulation, immune modulation, and genomic instability. Elevated MEX3A expression was correlated with unfavorable survival outcomes in several cancer types, supporting its potential value as a prognostic biomarker. In addition, the observed associations between MEX3A and immune checkpoint genes, immune modulators, tumor-infiltrating immune cells, TMB, MSI, and oncogenic pathways indicate that MEX3A may participate in shaping the tumor–immune microenvironment in a cancer-type-specific manner. However, these findings are primarily based on bioinformatics analyses of public bulk transcriptomic, proteomic, and clinical datasets. Therefore, the observed correlations do not establish causality or confirm MEX3A as a reliable therapeutic or immunotherapy target. Rather, MEX3A should be regarded as a promising candidate for further investigation. Future studies integrating independent clinical cohorts, immunotherapy-treated populations, single-cell and spatial transcriptomic analyses, and functional experiments using gain- and loss-of-function models are required to clarify the mechanistic role of MEX3A in tumor progression and immune regulation. Such validation will be essential before the clinical utility or therapeutic relevance of MEX3A can be firmly established. Electronic Supplementary Material Below is the link to the electronic supplementary material. Supplementary Material 3 Supplementary Material 3 Supplementary Material 3 Supplementary Material 4. Supplementary Material 5. Supplementary Material 6. Supplementary Material 7. Supplementary Material 8. Supplementary Material 9. Supplementary Material 10. Supplementary Material 11. Abbreviations Adrenocortical carcinoma Bladder Urothelial Carcinoma Breast invasive carcinoma Cervical squamous cell carcinoma and endocervical adenocarcinoma Cholangiocarcinoma Colon adenocarcinoma Lymphoid Neoplasm Diffuse Large B-cell Lymphoma Esophageal carcinoma Glioblastoma multiforme Head and Neck squamous cell carcinoma Kidney Chromophobe Kidney renal clear cell carcinoma Kidney renal papillary cell carcinoma Acute Myeloid Leukemia Brain Lower Grade Glioma Liver hepatocellular carcinoma Lung adenocarcinoma Lung squamous cell carcinoma Mesothelioma Ovarian serous cystadenocarcinoma Pancreatic adenocarcinoma Pheochromocytoma and Paraganglioma Prostate adenocarcinoma Rectum adenocarcinoma Sarcoma Stomach adenocarcinoma Skin Cutaneous Melanoma Testicular Germ Cell Tumors Thyroid carcinoma Thymoma Uterine Corpus Endometrial Carcinoma Uterine Carcinosarcoma Uveal Melanoma Author contributions Xuezhong Zhang and Xuebin Zhang proposed the study idea. Xuezhong Zhang, Yongxin Pan, Ning Li, Meilin Gao, Tingting Chu, Xuebin Zhang collected and analyzed the data. Xuezhong Zhang drafted the manuscript. Xuebin Zhang critically revised the manuscript. All authors contributed to the article and approved the submitted version. Funding This study is supported by grants from Natural Science Foundation of Dongying, China (2025ZRWS064, and 2025ZDJH11). Data availability RNA-seq and expression data for MEX3A should be referenced from the TCGA and GTEx datasets via UCSC XENA (Toil-processed, TCGA_GTEx, accession: [https://toil-xena-hub.s3.us-east-1.amazonaws.com/download/TcgaTargetGtex_rsem_gene_tpm.gz; Full metadata]), while protein expression data are available from CPTAC via UALCAN (MEX3A total and phosphoprotein S338/S462 datasets, accession: [https://ualcan.path.uab.edu/cgi-bin/CPTAC-Result-Phos.pl? genenam=MEX3A&ctype=Breast/OV/LUSC/LUAD]). Survival and clinical information can be sourced from the TCGA Pan-Cancer dataset (UCSC XENA, accession: [https://xenabrowser.net/datapages/]), and genetic alteration data from cBioPortal (TCGA Pan-Cancer studies, accession: [https://www.cbioportal.org/results/cancerTypesSummary? cancer_study_list=pancan_pcawg_2020&Z_SCORE_THRESHOLD=2.0&RPPA_SCORE_THRESHOLD=2.0&profileFilter=mutations%2Ccna&case_set_id=pancan_pcawg_2020_cnaseq&gene_list=MEX3A&geneset_list=%20&tab_index=tab_visualize&Action=Submit]). Data for RNA modification markers, immune checkpoint, and immune moderator genes were obtained from UCSC XENA (accession: [https://toil-xena-hub.s3.us-east-1.amazonaws.com/download/TcgaTargetGtex_rsem_gene_tpm.gz; Full metadata]), with immune infiltration results derived from TIMER2 (accession: [https://compbio.cn/timer2/MEX3A]). Finally, protein–protein interaction data were retrieved from STRING (minimum interaction score 0.150, accession: [https://cn.string-db.org/cgi/network? taskId=b0LCY4bXmfyo&sessionId=blx3c1MPn9sa]), and MEX3A-correlated genes from GEPIA2 (TCGA datasets, accession: [http://gepia2.cancer-pku.cn/#similar/MEX3A]).Research data are provided in Supplementary Table 1 (The expression of MEX3A in each cancer type), Supplementary Table 2 (The relationship between MEX3A and overall survival (OS) in each cancer type), Supplementary Table 3 (The relationship between MEX3A and disease specific survival (DSS) in each cancer type), Supplementary Table 4 (The correlation coefficient and P value of RNA modification analysis of MEX3A in various tumor types), Supplementary Table 5 (Correlation analysis between MEX3A expression and immune checkpoints), Supplementary Table 6 (Correlation analysis between MEX3A expression and immune Moderator Genes), Supplementary Table 7 (The origion data of MEX3A expression correlated withTumor Mutational Burden (TMB) expression in cancer), Supplementary Table 8 (The origion data of MEX3A expression correlated with Microsatellite Instability (MSI) expression in cancer). Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Xuezhong Zhang, Yongxin Pan and Ning Li shares first authorship. References Associated Data Supplementary Materials Supplementary Material 3 Supplementary Material 3 Supplementary Material 3 Supplementary Material 4. Supplementary Material 5. Supplementary Material 6. Supplementary Material 7. Supplementary Material 8. Supplementary Material 9. Supplementary Material 10. Supplementary Material 11. Data Availability Statement RNA-seq and expression data for MEX3A should be referenced from the TCGA and GTEx datasets via UCSC XENA (Toil-processed, TCGA_GTEx, accession: [https://toil-xena-hub.s3.us-east-1.amazonaws.com/download/TcgaTargetGtex_rsem_gene_tpm.gz; Full metadata]), while protein expression data are available from CPTAC via UALCAN (MEX3A total and phosphoprotein S338/S462 datasets, accession: [https://ualcan.path.uab.edu/cgi-bin/CPTAC-Result-Phos.pl? genenam=MEX3A&ctype=Breast/OV/LUSC/LUAD]). Survival and clinical information can be sourced from the TCGA Pan-Cancer dataset (UCSC XENA, accession: [https://xenabrowser.net/datapages/]), and genetic alteration data from cBioPortal (TCGA Pan-Cancer studies, accession: [https://www.cbioportal.org/results/cancerTypesSummary? cancer_study_list=pancan_pcawg_2020&Z_SCORE_THRESHOLD=2.0&RPPA_SCORE_THRESHOLD=2.0&profileFilter=mutations%2Ccna&case_set_id=pancan_pcawg_2020_cnaseq&gene_list=MEX3A&geneset_list=%20&tab_index=tab_visualize&Action=Submit]). Data for RNA modification markers, immune checkpoint, and immune moderator genes were obtained from UCSC XENA (accession: [https://toil-xena-hub.s3.us-east-1.amazonaws.com/download/TcgaTargetGtex_rsem_gene_tpm.gz; Full metadata]), with immune infiltration results derived from TIMER2 (accession: [https://compbio.cn/timer2/MEX3A]). Finally, protein–protein interaction data were retrieved from STRING (minimum interaction score 0.150, accession: [https://cn.string-db.org/cgi/network? taskId=b0LCY4bXmfyo&sessionId=blx3c1MPn9sa]), and MEX3A-correlated genes from GEPIA2 (TCGA datasets, accession: [http://gepia2.cancer-pku.cn/#similar/MEX3A]).Research data are provided in Supplementary Table 1 (The expression of MEX3A in each cancer type), Supplementary Table 2 (The relationship between MEX3A and overall survival (OS) in each cancer type), Supplementary Table 3 (The relationship between MEX3A and disease specific survival (DSS) in each cancer type), Supplementary Table 4 (The correlation coefficient and P value of RNA modification analysis of MEX3A in various tumor types), Supplementary Table 5 (Correlation analysis between MEX3A expression and immune checkpoints), Supplementary Table 6 (Correlation analysis between MEX3A expression and immune Moderator Genes), Supplementary Table 7 (The origion data of MEX3A expression correlated withTumor Mutational Burden (TMB) expression in cancer), Supplementary Table 8 (The origion data of MEX3A expression correlated with Microsatellite Instability (MSI) expression in cancer).